对血管素II的临床经验分析:一个元分析和4个AI
Íñigo Isern-de-Val1, Saray Antón Juarros2, Marta Malingre Gajino2
1Intensive Care Unit, University Hospital Lozano Blesa, Zaragoza, Spain; GIE of Critics, Health Research Institute of Aragon (IIS Aragón), Zaragoza, Spain.
Medicina intensiva
|November 11, 2025
概括
ангиотензин II (ATII) 有效地提高血压,而不会增加死亡率或副作用. 人工智能 (AI) 工具可以帮助分析分布性休克中ATII的临床证据.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 医疗信息学 医疗信息学
背景情况:
- ангиотензин II (ATII) 在西班牙于2023年获得治疗分布性休克的批准.
- 评估ATII的临床证据对于其有效实施至关重要.
研究的目的:
- 评估 ангиотензин II (ATII) 在分布性休克中的疗效和安全性.
- 将元分析 (MTA) 的结果与四种人工智能 (AI) 工具产生的结果进行比较.
主要方法:
- 在主要数据库 (PubMed,CENTRAL,Embase,Scopus) 进行了全面的文献搜索.
- 包括的研究包括随机临床试验,非随机试验和关注死亡率,疗效和安全结果的观察性研究.
- 数据使用元分析 (MTA) 进行合成,并使用人工智能工具 (共识,困惑,诱导,Scite) 进行分析.
主要成果:
- ATII 显示了所有原因死亡率降低的趋势 (OR 0.86),高素水平 (OR 0.45) 和需要替代疗法 (OR 0.38) 的子组显著降低.
- ATII显著增加了平均动脉压 (OR 3.25) 没有相应增加的不良事件 (OR 0.77).
- 人工智能工具证实了MTA的发现,尽管它们包含了较小比例的总确定研究.
结论:
- ангиотензин II (ATII) 有效提高分布性休克患者的血压,对死亡率或增加不良事件没有显著影响.
- 人工智能 (AI) 是一个有希望的工具,可以帮助评估药理干预的临床证据.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
Hypertension II: Pathophysiology
765
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
765
Hypertension IV: Drug Therapy and Lifestyle Modifications
600
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
600


